Alkermes Q3 revenue $394.2M, GAAP EPS $0.49; raises FY2025 guidance

Alkermes plc.

2025-Q3 EPS reported $1.14 vs consensus $0.31 ▲ beat (+271.8%)

Q3 total revenues $394.2M up 4% YoY; proprietary net sales $317.4M up 16% YoY.
LYBALVI sales $98.2M (+32% YoY); ARISTADA $98.1M (+16% YoY); VIVITROL $121.1M (+7% YoY).
GAAP net income $82.8M vs $92.4M in Q3 2024; diluted EPS $0.49.
FY2025 revenue guidance raised to $1.43-1.49B from $1.34-1.43B; GAAP net income now $230-250M.
CEO highlighted proposed Avadel acquisition and positive phase 2 data for alixorexton in narcolepsy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.